Trial Profile
Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine Hecolin® in Seniors Aged Over 65 Years
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
- Indications Hepatitis E
- Focus Adverse reactions
- 15 Aug 2018 Status changed from recruiting to completed.
- 08 Aug 2014 New trial record